Mustang Bio MBIO
NASDAQ MBIO
$0.48 +0.01 (+2.13%)
At close: Oct 2, 2026 · 4:00 PM EDT

Mustang Bio (MBIO) Gains from Sales and Divestitures (2022)

Updated

Mustang Bio's Gains from Sales and Divestitures came in at -$29,000 for FY2024.

Analysis

Mustang Bio (MBIO) Gains from Sales and Divestitures (2022) Analysis & Trends

  • Per Business Quant, earlier years put Gains from Sales and Divestitures at -$255,000 in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Mustang Bio 3.23 Mn 3.23 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 -494,000.00
API Access

Mustang Bio Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=MBIO&period=max&api_key=YOUR_API_KEY